Currently, there are 56.98M common shares owned by the public and among those 46.84M shares have been available to trade.
Insiders at the company have transacted a total of 176 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 36 of these insider trades were purchases, accounting for 601,413 shares. Insider sales of the common stock occurred on 140 occasions, with total insider shares sold totaling 11,829,488 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 7.25, up 16.29%. The company’s stock has a 5-day price change of 168.40% and 187.98% over the past three months. VTYX shares are trading 171.66% year to date (YTD), with the 12-month market performance down to -84.33% lower. It has a 12-month low price of $1.87 and touched a high of $47.25 over the same period. VTYX has an average intraday trading volume of 3.90 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 154.94%, 177.25%, and -67.83% respectively.
Institutional ownership of Ventyx Biosciences Inc (NASDAQ: VTYX) shares accounts for 73.36% of the company’s 56.98M shares outstanding.
It has a market capitalization of $395.69M and a beta (3y monthly) value of -0.04. The earnings-per-share (ttm) stands at -$3.12. Price movements for the stock have been influenced by the stock’s volatility, which stands at 33.74% over the week and 13.68% over the month.
Analysts forecast that Ventyx Biosciences Inc (VTYX) will achieve an EPS of -$0.9 for the current quarter, -$0.87 for the next quarter and -$2.87 for 2024. The lowest estimate earnings-per-share for the quarter is -$1.24 while analysts give the company a high EPS estimate of -$0.62. Comparatively, EPS for the current quarter was -$0.62 a year ago. Earnings per share for the fiscal year are expected to decrease by -62.76%, and 12.23% over the next financial year.
Looking at the support for the VTYX, a number of firms have released research notes about the stock. Wells Fargo stated their Equal Weight rating for the stock in a research note on November 07, 2023, with the firm’s price target at $77-$8. Stifel coverage for the Ventyx Biosciences Inc (VTYX) stock in a research note released on November 07, 2023 offered a Hold rating with a price target of $6. Oppenheimer was of a view on November 07, 2023 that the stock is Perform, while Morgan Stanley gave the stock Equal-Weight rating on November 07, 2023, issuing a price target of $46- $6. H.C. Wainwright on their part issued Neutral rating on November 07, 2023.
